Title: Phase IB Results of a Multi-Center Randomized Phase IB/II Study of Gemcitabine and Cisplatin With or Without CPI-613 (Devimistat) as First-Line Therapy for Patients with Advanced Biliary Tract Cancer (BilT-04)
Title: Phase 1b results of a multicenter, randomized phase 1b/2 study of gemcitabine and cisplatin +/- CPI-613 as first-line therapy for patients with advanced biliary tract cancer (BilT-04)
Title: Phase 1/2 study of devimistat in combination with hydroxychloroquine (HCQ) in patients with relapsed or refractory (R/R) clear cell sarcoma (CCS)
Title: Phase 3, multicenter, randomized study of CPI-613 with modified FOLFIRINOX (mFFX) versus FOLFIRINOX (FFX) as first-line therapy for patients with metastatic adenocarcinoma of the pancreas (AVENGER500)
July 11-13, 2022 | Hynes Center, Boston, MA
Our President & CEO, Sanjeev Luther, was honored to speak at this year’s World Orphan Drug Congress. Sanjeev joined a panel discussion with leading experts in the rare disease ecosystem to discuss leveraging & managing relationships within the rare cancer space.
During the event, Sanjeev shared: “Help us help them. Passion and hope!! Never give up. Fight and fight until we get the outcome we want.
A Multi-Center Randomized Phase IB/II Study of Gemcitabine and Cisplatin With or Without CPI-613® as First-Line Therapy for Patients with Advanced Unresectable Biliary Tract Cancer: BilT-04
A phase II open-label study of CPI-613® in combination with modified (m) FOLFIRINOX in patients with locally advanced pancreatic cancer
ARMADA 2000: Phase III Multicenter Open-Label Rfa ntdhoem iPzeadn Tcrriael atos Evaluate Efficacy and Safety of CPI-613® (devimistat) in Combination with High Dose Cytarabine and Mitoxantrone (CHAM) Compared to High Dose Cytarabine and Mitoxantrone (HAM) in Older Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML)
A Phase II Clinical Trial of CPI-613® (devimistat) in Patients with Relapsed or Refractory Burkitt Lymphoma/Leukemia or High-grade B-cell Lymphoma with Rearrangements of MYC and BCL2 and/or BCL6 (DHL/THL)
Phase I study of CPI-613 in combination with Bendamustine for relapsed and refractory T cell lymphoma
TCA Cycle Inhibition by CPI-613 Increases Sensitivity to Chemotherapy in Older and Poor Risk Acute Myeloid Leukemia (AML)
CPI-613 enhances FOLFIRINOX response rate in stage IV pancreatic cancer
The Mitochondrial Metabolism inhibitor CPI-613 in combination with mFOLFIRINOX for pancreatic cancer.
The Mitochondrial Metabolism Inhibitor CPI-613 in Combination with High Dose Ara-C (HDAC) and Mitoxantrone is Highly Active in High Risk Relapsed or Refractory AML.
The Mitochondrial Metabolism Inhibitor CPI-613 in Combination with High Dose Ara-C (HDAC) and Mitoxantrone is Highly Active in Poor Risk Relapsed or Refractory Acute Myeloid Leukemia (AML).
A phase I Study of the Mitochondrial Metabolism Inhibitor CPI-613 in Combination with High Dose Ara-C and Mitoxantrone for Relapsed or Refractory Acute Myeloid Leukemia
A Phase I Study of the First in Class Mitochondrial Metabolism Inhibitor CPI-613 in Patients with Advanced Hematologic Malignancies
Translational Assessment of the Efficacy of CPI-613 Against Pancreatic Cancer in Animal Models Vs. Patients With Stage IV Disease
Evaluation of the first-in-class antimitochondrial metabolism agent CPI-613 in hematologic malignancies
Lipoic acid analogs induces ROS, leading to potent mitochondrial enzyme inhibition, metabolic dysfunction and cell death in tumor cells
Regulation of Pancreatic, Gliosarcoma, and Non-Small Lung Cancer via CPI-613, a Novel Selective Anticancer Therapeutic Agent
Altered Lipid and Mitochondrial Metabolism are viable Targets in Acute Leukemia
Poster: Potent anti-cancer agents, non-redox-active lipoate derivatives, have pervasive, catastrophic regulatory effects on cancer cell metabolism
